BioCentury
ARTICLE | Company News

Ascletis submits Chinese NDA for second HCV therapy

July 31, 2018 9:23 PM UTC

Ahead of its Hong Kong trading debut Wednesday, Ascletis Pharma Inc. (HKSE:1672) said Tuesday it submitted an NDA to China's State Drug Administration for HCV therapy ravidasvir. The second-generation HCV NS5A protein inhibitor received expedited review from the agency in 2016.

In June, Ascletis launched HCV drug Ganovo danoprevir in China. Ascletis has rights to the HCV NS3/4A protease inhibitor from Roche (SIX:ROG; OTCQX:RHHBY) in China, Hong Kong, Macau and Taiwan...

BCIQ Company Profiles

Ascletis Pharma Inc.

BCIQ Target Profiles

HCV NS5A protein